Abstract Objective To systematically investigate the efficacy and safety of glucocorticoids (GCs) combined with intravenous injection of immunoglobulin (IVIG) in the initial treatment of Kawasaki disease (KD). Methods MEDLINE Database, PubMed Database, CNKI, Wanfang Data, and VIP Database were searched to collect prospective or retrospective controlled studies on the combination of GCs and IVIG as the initial treatment of KD, which were published up to March 2016. Two investigators independently screened the literature, extracted data, and assessed the quality of the articles included. Then, a Meta analysis was performed using RevMan 5.2 software. Results A total of 11 articles in English were included, with 7 prospective studies and 4 retrospective studies. The results of the Meta analysis showed that compared with the group using IVIG alone, the combination group had a significantly lower incidence rate of coronary artery lesion (CAL) (OR = 0.44, 95%CI 0.23-0.86, P = 0.02) and a significantly shorter duration of fever (MD = -1.66, 95%CI -2.32 to -1.01, P < 0.00001). The combination group had a significantly lower rate of no response to initial treatment than the IVIG alone group (OR = 0.37, 95%CI 0.27-0.51, P < 0.00001). The recurrence rate of KD and the incidence rate of adverse events showed no significant differences between the two groups. Conclusions GCs combined with IVIG as the initial treatment for KD can reduce the incidence rate of CAL and the rate of no response to initial treatment and shorten the duration of fever, and does not increase the recurrence rate of KD and the incidence rate of adverse events.
LI Jing,WANG Bo-Long,FENG Rui-Bing et al. Efficacy of glucocorticoids combined with immunoglobulin in initial treatment of Kawasaki disease: a Meta analysis[J]. CJCP, 2016, 18(6): 527-533.
LI Jing,WANG Bo-Long,FENG Rui-Bing et al. Efficacy of glucocorticoids combined with immunoglobulin in initial treatment of Kawasaki disease: a Meta analysis[J]. CJCP, 2016, 18(6): 527-533.
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement[J]. Pediatrics, 1979, 63(2): 175-179.
[3]
Kuaskawa S. Long-term administrative care of Kawasaki disease[J/OL]. Acta Pediatr Jap, 1983, 25 (2): 205-209.
[4]
Millar K, Manlhiot C, Yeung RS, et al. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression [J]. Int J Cardiol, 2012: 154(1): 9-13.
[5]
Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial[J]. Lancet, 2012, 379 (9826): 1613-1620.
[6]
Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease[J]. Eur J Pediatr, 2009, 168(2): 181-185.
[7]
Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children[J]. Pediatrics, 2005, 116(4): 989-995.
[8]
Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease[R]. Tokyo: Ministry of Health and Welfare, 1984.
[9]
Council on Cardiovascular Disease in the Young; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; American Heart Association. Diagnostic guidelines for Kawasaki disease[J]. Circulation, 2001, 103(2): 335-336.
[10]
Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis[J]. Hepatology, 2002, 35(3): 609-615.
[11]
Wells GA, Shea B, Connell DO, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses[J]. Appl Eng Agric, 2002, 18(6): 727-734.
[12]
Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease[J]. J Pediatr, 1999, 135(4): 465-469.
[13]
Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial[J]. J Pediatr, 2003, 142(6): 611-616.
[14]
Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children[J]. J Pediatr, 2003, 143(3): 363-367.
[15]
Jibiki T, Terai M, Kurosaki T, et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease[J]. Eur J Pediatr, 2004, 163(4-5): 229-233.
[16]
Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome[J]. J Pediatr, 2006, 149(3): 336-341.
[17]
Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease[J]. N Engl J Med, 2007, 356(7): 663-675.
[18]
Kobayashi T, Inoue Y, Otani T, et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease[J]. Pediatr Infect Dis J, 2009, 28(6): 498-502.
[19]
Ogata S, Ogihara Y, Honda T, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial[J]. Pediatrics, 2012, 129(1): e17-e23.
[20]
Lim YJ, Jung JW. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease[J]. Yonsei Med J, 2014, 55(5): 1260-1266.
[21]
Jia S, Li C, Wang G, et al. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease[J]. Clin Exp Immunol, 2010, 162(1): 131-137.
